The US Food and Drug Administration has issued guidance urging sponsors and trial sites to consider the necessity of the invasive procedure.

The trial’s secondary endpoints assessed respiratory function and muscle strength, with no significant difference observed between the two cohorts. Credit: David Herraez Calzada / Shutterstock.

CytoMed Therapeutics has signed a business and research collaboration agreement with SunAct Cancer Institute for a clinical trial in India.

VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel for treating non-segmental vitiligo.

After disappointing Phase IIb results for avicursen in December, Percheron will adopt a three-pronged business strategy.

Oculis has reported that the Phase II ACUITY trial of OCS-05, in treating individuals with acute optic neuritis, met the primary endpoint ...

Chime Biologics and Mabgeek have completed the Process Performance Qualification (PPQ) for the humanised anti-IL-4Rα monoclonal antibody, MG-K10, advancing it into Phase III clinical trials for a ...

The Australian Government has announced the ‘2024 Clinical Trial Enabling Infrastructure’ grant opportunity, offering A$35.7m for research.

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.

Hanx Biopharmaceuticals has dosed the first subject in a trial of HX044, a bispecific antibody designed for advanced solid tumours.

According to GlobalData, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since 2004.